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ABSTRACT
Recent studies have shown that Sca-11 (stem cell antigen-1) stem/progenitor cells within blood
vessel walls may contribute to neointima formation, but the mechanism behind their recruit-
ment has not been explored. In this work Sca-11 progenitor cells were cultivated from mouse
vein graft tissue and found to exhibit increased migration when cocultured with smooth muscle
cells (SMCs) or when treated with SMC-derived conditioned medium. This migration was associ-
ated with elevated levels of chemokines, CCL2 (chemokine (C-C motif) ligand 2) and CXCL1 (che-
mokine (C-X-C motif) ligand 1), and their corresponding receptors on Sca-11 progenitors, CCR2
(chemokine (C-C motif) receptor 2) and CXCR2 (chemokine (C-X-C motif) receptor 2), which
were also upregulated following SMC conditioned medium treatment. Knockdown of either
receptor in Sca-11 progenitors signiﬁcantly inhibited cell migration. The GTPases Cdc42 and
Rac1 were activated by both CCL2 and CXCL1 stimulation and p38 phosphorylation was
increased. However, only Rac1 inhibition signiﬁcantly reduced migration and p38 phosphoryla-
tion. After Sca-11 progenitors labeled with green ﬂuorescent protein (GFP) were applied to the
adventitial side of wire-injured mouse femoral arteries, a large proportion of GFP-Sca-11-cells
were observed in neointimal lesions, and a marked increase in neointimal lesion formation was
seen 1 week post-operation. Interestingly, Sca-11 progenitor migration from the adventitia to
the neointima was abrogated and neointima formation diminished in a wire injury model using
CCL22/2 mice. These ﬁndings suggest vascular stem/progenitor cell migration from the adventi-
tia to the neointima can be induced by SMC release of chemokines which act via CCR2/Rac1/
p38 and CXCR2/Rac1/p38 signaling pathways. STEM CELLS 2016;34:2368–2380
SIGNIFICANCE STATEMENT
In the present article, we provide the first evidence that vascular smooth muscle cell produced
chemokine CCL2 and CXCL1 play a key role in mediating resident stem cell migration from the
adventitia to intima, where they are composed of neointimal lesions in mouse model. This can
be reverted by the chemokine gene CCL2 knockout. We feel that our findings provide a new
insight into the mechanisms of vascular stem cell migration with a therapeutic potential for
restenosis, which would be interesting for the readers.
INTRODUCTION
Smooth muscle cells (SMCs) are well estab-
lished as a key cell type that can contribute to
the pathology of vascular diseases such as ath-
erosclerosis and post-angioplasty restenosis
[1–3]. Increasing evidence suggests that during
vascular injury, SMCs in the media layer of the
vessel undergo dedifferentiation from a quies-
cent/contractile phenotype to an active/syn-
thetic phenotype and contribute to neointima
formation through increased cell proliferation
and migration [4, 5]. During this process, SMCs
secrete a variety of chemokines such as che-
mokine (C-C motif) ligand 2 (CCL2) and (C-X-C
motif) ligand 1 (CXCL1) [6]. These chemokines
are largely responsible for recruitment of
inﬂammatory cells [7, 8]. For example, after
vascular injury, CCL2 is released by SMCs in a
hypercholesterolemia mouse model and simul-
taneously chemokine (C-C motif) receptor 2
(CCR2) is upregulated on monocytes, which
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leads to over-recruitment of leukocytes to lesion sites [9, 10].
In ApoE2/2mice CXCL1 presented by the lesion-prone endo-
thelium triggers monocyte recruitment in a process depend-
ent on a4b1 integrin [11]. In the late stage of atherosclerotic
lesion development, CXCL1 is also important for macrophage
accumulation via leukocyte expression of chemokine (C-C
motif) receptor 2 (CXCR2) [12]. Additionally, neutralization of
CXCL1 reduces endothelial chemotaxis in vitro and delays
endothelial recovery after arterial injury in vivo in a CXCR2-
dependent manner [13]. However, little is known about the
roles of CCL2 and CXCL1 secreted by SMCs in recruitment of
other cell types, for example, vascular resident stem/progeni-
tor cells, into the intima in response to injury.
Recently, studies from several laboratories have identiﬁed
the presence of a range of multipotent and lineage-restricted
stem/progenitor cells in the adventitia of the vessel wall.
These cells possess high potential to differentiate into many
cell lineages, including endothelial and SMCs, adipocytes and
osteoblasts [14–16]. Progenitor cells residing in the adventitia
are positive for the stem/progenitor markers stem cell
antigen-1 (Sca-1) and c-kit [17]. In our recent studies, we
have shown that Sca-11 cells can migrate toward sirolimus, a
drug used to coat stents [18], and differentiate into SMCs in
vitro and in an ex vivo model of decellularized vessels [17,
19]. However, it is unknown whether chemokines released
from SMCs in response to injury play a role in attracting vas-
cular stem cells. The aims of this study were to investigate
whether local SMC-released chemokines can induce
adventitial-derived resident progenitor cell migration and to
elucidate the mechanism behind progenitor cell promotion of
neointima formation after vessel injury. In the present report,
we demonstrate that SMCs can induce Sca-11 progenitor cell
migration upon the release of CXCL1 and CCL2, which in turn
activate the Rac1/p38 MAPK signaling pathways via the recep-
tors CXCR2 and CCR2 respectively. Importantly, we demon-
strate that CCL2-deﬁcent mice display reduced Sca-11 cell
migration and neointima formation in response to vessel
injury.
MATERIALS AND METHODS
Mouse Vascular Progenitor Cell Culture
The vena cava of a C57BL/6J mouse (Harlan, Blackthorn,
Bicester, UK) was isografted to the carotid artery of an iso-
genic mouse or GFP C57BL/6J mouse (Jackson Laboratory, Bar
Harbour, Maine, USA). After 2 weeks, graft tissues were har-
vested and explanted in gelatin-coated ﬂasks. Culture was in
complete stem cell culture medium.
Cell Sorting
Vascular progenitor cells (VPCs) were sorted with anti-Sca-1
immunomagnetic microbeads (Miltenyi Biotec, GmbH, Ber-
gisch Gladbach, Germany) and then selected using a magnetic
cell separator (Miltenyi Biotec, GmbH, Bergisch Gladbach, Ger-
many). Sca-11 VPC populations were expanded for up to 5
population doublings.
Statistical Analysis
Data for this study are presented as the mean6 standard
error of the mean (SEM.) of at least three separate experi-
ments. Analysis was performed using Graphpad Prism V.6
(GraphPad Software, San Diego, CA) using analysis of variance
(one way ANOVA) followed by Dunnett’s multiple comparison
tests. Signiﬁcance was considered when p< .05.
Detailed Methods are included in the Supporting Informa-
tion Online Data.
RESULTS
Characterization of Vascular Stem/Progenitor Cells
Previously published works by our group identiﬁed a popula-
tion of progenitor cells within pathological vessels from a
mouse vein graft model [19, 20]. As in this previous work, 2
weeks after implantation of vein grafts, a large heterogeneous
population of cells was found to migrate from the adventitia
of vessels and contributed to neointima formation [17]. Cells
were isolated from the adventitia and used to derive clones
of single cells. Immunoﬂuorescent staining showed that cells
from this cloned population express progenitor cell marker
Sca-1 (Supporting Information Fig. 1A, 1B), but express very
few SMC or endothelial cell markers (Supporting Information
Fig. 1C, 1D). In order to purify a larger pool of Sca-11 progen-
itor cells from the initially heterogeneous adventitial popula-
tion anti-Sca-1 immunomagnetic microbeads were used.
Approximately 15% of total cells collected using this method
was identiﬁed as Sca-11 progenitor cells after sorting (Data
not shown). Sca-11 cells derived from clones and a mixed
population of Sca-11 progenitor cells derived by magnetic
sorting were further characterized by a qPCR array showing
gene expression of chemokines and chemokine receptors, fur-
ther details are described in the following results. Our hypoth-
esis is that Sca-11 progenitors may contribute to the
pathology of atherosclerosis, potentially via their expression
of chemokines and receptors.
SMC-Conditioned Medium Induced VPC Migration
To investigate whether SMCs inﬂuence the migratory capacity
of VPCs, a transwell migration assay was performed. Increas-
ing numbers of SMCs were seeded on the base of the lower
chamber while ﬁxed numbers of VPCs were seeded on the
8.0 mm pore membrane of the upper chamber. Using an
increasing ratio of VPCs to SMCs (from 1:0 to 1:5), and allow-
ing an overnight incubation, we found that the migration of
VPCs increased as the number of SMCs increased and this
reached its peak when the VPC:SMC ratio was 1:2 (Fig. 1A).
Next, SMC-conditioned medium was collected from SMC cul-
tured overnight in serum free medium and used for migration
assays. Addition of SMC-conditioned medium consistently
stimulated VPC migration in both transwell and wound
healing assays, when compared to serum free medium.
(Fig. 1B, 1C).
Time lapse microscopy was used to track the speed and
the persistence of single progenitor cells during their migra-
tion when treated with SMC conditioned medium in an over-
night incubation. These results showed that SMC-conditioned
medium augmented directional persistence of VPC migration,
while migrational velocity remained unaltered between the
treatments (Fig. 1D–1F and Supporting Information online
Video 1 (control), Supporting Information online Video 2
(SMC conditioned medium)). Use of a BrdU cell proliferation
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assay conﬁrmed that this effect was not due to proliferation
(Supporting Information Fig. 2A). qPCR analysis revealed that
the mRNA levels of SMC markers (calponin and a-SMA) and
endothelial marker (CD31) in VPCs were not signiﬁcantly
changed during the experiment (Supporting Information Fig.
2B–2D). VPCs also maintained progenitor characteristics, as
the progenitor marker Sca-1 was not signiﬁcantly changed
when compared to the control (Supporting Information Fig.
2E). Additionally, immunoﬂuorescence staining for paxillin, vin-
culin and phosphorylated FAK showed that relocation of
cytoskeleton-related proteins was increased (Supporting Infor-
mation Fig. 3A). Taken together, the above results support the
notion that both coculture with SMC and SMC-derived condi-
tioned medium can induce VPC migration.
SMC-Released CCL2 and CXCL1 Induced VPC Migration
To further investigate which mediators released by SMCs
were responsible for the conditioned medium induced VPC
migration, we performed a chemokine multi-ELISA array. This
revealed that CXCL1 and CCL2 levels were markedly increased
in SMC-conditioned medium when compared to serum free
medium (Fig. 2A). Murine CCL2 or CXCL1 Quantikine kits
established that the amounts of CCL2 and CXCL1 in the condi-
tioned medium were 4.636 1.29 ng/ml and CXCL1
3.086 0.99 ng/ml, respectively, (Fig. 2B, 2C). While the level
of CCL5 was also upregulated in comparison to the control,
subsequent transwell migration assays found that it did not
affect VPC migration (Supporting Information Fig. 4A, 4B). To
conﬁrm the roles of CCL2 and CXCL1 in mediating VPC migra-
tion, we performed transwell and wound healing assays using
exogenous mouse recombinant CCL2 and CXCL1 proteins,
respectively. VPC migration was enhanced by CCL2 and CXCL1
treatment and peaked at 5 ng/ml (a sixfold increase in CCL2
and a twofold increase in CXCL1 treated cells) (Fig. 2D, 2E).
These were similar concentrations of CCL2 and CXCL1 to
those measured in SMC-derived conditioned medium. That a
5 ng/ml CCL2 or CXCL1 treatment enhanced VPC migration
was conﬁrmed by wound healing assay (Fig. 2F, 2G). Silencing
of CCL2 or CXCL1 in the SMCs using siRNAs resulted in signiﬁ-
cant down-regulation of CCL2 and CXCL1 at both the mRNA
and protein levels (Fig. 2H–2K). Importantly, CCL2 or CXCL1
depleted SMCs failed to stimulate VPC migration in transwell
assays (Fig. 2L, 2M). To further investigate the relationship
between CCL2 and CXCL1 in SMC conditioned medium
induced VPC migration, CCL2 and/or CXCL1 concentrations
were depleted using their corresponding neutralizing antibod-
ies. The antibodies were found to be effective and selective
as they signiﬁcantly reduced the availability of their target
chemokine while they had no effect on the other chemokine
Figure 1. SMC conditioned medium can induce VPCs migration.
(A): Chemotaxis of vascular progenitor cells (5 3 104 cells/well)
across 8.0 lm transwells toward an increasing number of SMCs
after 18 hours was documented after 0.1% crystal violet staining.
Serum free culture medium was used as control for all migration
experiments, n5 5. Scale bars, 100mm. (B, C): Migration of vascu-
lar progenitor cells in response to SMC conditioned medium. Che-
motaxis index was deﬁned by average of 9 ﬁelds of view and was
presented as fold increase compared to the control, n5 5. Scale
bars, 100 mm. (D–F): Vascular progenitor cells were incubated
with or without SMC conditioned medium for 20 hours. Time
lapse microscopy was performed to observe single cell move-
ment. Trajectory plots of migrating VPC are shown in (D), 100
tracked single cells in each group are displayed. Quantiﬁcation
analysis of the speed (E) and persistence (F) of VPC were per-
formed in 3 independent experiments. All graphs are shown as
mean6 SEM. *p< .05, **p< .01, ***p< .001. ns, p> .05. Abbre-
viations: ctrl, control, serum free medium; CM, SMC conditioned
medium; SMC, smooth muscle cell; VPCs, vascular progenitor
cells.
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Figure 2. CCL2 and CXCL1 released from SMC conditioned medium induced VPCs migration. (A): The identiﬁcation of chemokines in
SMC conditioned medium using a Chemokine Multiarray ELISA kit. The graph indicates the absorbance of each chemokine at 450 nm.
n5 3. (B, C): The concentrations of CCL2 and CXCL1 in SMC conditioned medium were quantiﬁed by the murine CCL2 or CXCL1 Quanti-
kine ELISA kit. n 5 3. (D, E): Changes in vascular progenitor cells migration in response to a gradient of CCL2 or CXCL1 in serum free
culture medium were evaluated using a transwell assay. n5 5. Scale bars, 50 mm. (F, G): Wound healing assay was performed on vascu-
lar progenitor cells treated with CCL2 (5 ng/ml), CXCL1 (5 ng/ml) or vehicle control. Graphs are shown as fold increase relative to con-
trols. Scale bars, 100 mm. SMCs were transfected either with control noncoding small interfering RNA (siRNA), CCL2 siRNA (300 nM) or
CXCL1 siRNA (100 nM) to knockdown corresponding mRNA. The real-time quantitative PCR and Quantikine ELISA kit showed the folds
decrease in mRNA (H, J) and protein (I, K) levels in CCL2 or CXCL1 siRNA transfected SMCs and their conditioned medium respectively.
n 5 3. (L, M): Transwell assay was performed on vascular progenitor cells migrating toward SMC (transfected either with noncoding
siRNA, CCL2 siRNA or CXCL1 siRNA) conditioned medium. n 5 5. Scale bars, 50mm. All graphs are shown as mean6 SEM. **p< .01,
***p< .001. Abbreviations: ctrl, control, serum free medium; NCsi, noncoding siRNA; siCCL2, CCL2 siRNA; siCXCL1, CXCL1 siRNA; CM,
SMC conditioned medium; SMC, smooth muscle cell.
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studied. Depletion of either CCL2 or CXCL1 did not result in a
compensatory release of the other chemokine and there
appeared to be no interactions between the two antibodies
(Supporting Information Fig. 5A, 5B). Having conﬁrmed the
effectiveness of the neutralizing antibodies they were used to
study the role of CCL2 and CXCL1 in VPC migration. Depletion
of either CCL2 or CXCL1 in SMC conditioned medium inhibited
migration of VPCs by nearly 50%. However, simultaneous
depletion of CCL2 and CXCL1 in SMC conditioned medium did
not further reduce this migration level (Supporting Informa-
tion Fig. 5C, 5D). Finally, incubation with various concentra-
tions of CCL2 or CXCL1 did not stimulate VPCs autocrine
production of the other chemokine (Supporting Information
Fig. 5E, 5F). Taken together, these results suggest that
although CCL2 and CXCL1 derived from SMCs play an impor-
tant role in the induction of VPC migration, their interaction
is neither cumulative nor redundant but both are required for
migration to be induced.
VPC Migration is Mediated by CCR2 and CXCR2
Each chemokine needs to interact with its corresponding
receptor in order to exert an effect. We investigated the che-
mokine receptor proﬁle of VPCs by performing a qPCR-array
of a mixed population of Sca-11 progenitor cells derived by
magnetic sorting and Sca-11 cells derived from a clone. We
demonstrated that VPCs possess a variety of chemokine
receptors (Fig. 3A, Supporting Information Table 2) and impor-
tantly, CCR2 and CXCR2, the corresponding receptors of CCL2
and CXCL1. Both mRNA and protein level expression of these
receptors was signiﬁcantly upregulated after treatment with
SMC conditioned medium (Fig. 3B–3E). To silence CCR2 and
CXCR2 in VPCs at the gene level, VPCs were infected with
CCR2 or CXCR2 lentiviral shRNA while a null shRNA was also
introduced into VPCs as a control. The cells were selected for
4-5 days using neomycin and maintained in complete culture
medium. Subsequent transwell migration experiments with
CCR2 or CXCR2 silencing resulted in a signiﬁcant decrease in
VPC migration (Fig. 3F). In addition, pretreatment with antag-
onists of CCR2 or CXCR2 led to downregulation of VPC migra-
tion in response to chemokines (Supporting Information Fig.
6A, 6B). These ﬁndings suggest that CCL2 and CXCL1 released
from SMCs induce VPC migration via interaction with their
corresponding receptors CCR2 and CXCR2.
CCL2 and CXCL1 Induced VPCs Migration Through the
Rac1-p38 Pathways
The Rho GTPase family members Rac1 and Cdc42 have been
implicated as important regulators of cell migration [21]. To
investigate whether Cdc42 and Rac1 are involved in VPC
migration, we measured the level of GTP-Cdc42 and GTP-Rac1
using pull down assays. Stimulation of VPCs with mouse
recombinant CCL2 or CXCL1 resulted in both Cdc42 and Rac1
activation (Fig. 4A, 4B). Treatment with either ML141 (an
inhibitor of Cdc42) or NSC23766 (an inhibitor of Rac1)
resulted in a signiﬁcant reduction in VPC migration induced
by CCL2 and CXCL1 as compared to control (Fig. 4C, 4D).p38
MAPK has been identiﬁed as the down-stream signal trans-
ducer of active forms of Cdc42 and Rac1 and the p38 signal-
ing pathway can induce rearrangements of the cytoskeleton
that regulate cell migration [22, 23]. A time course using
Western blotting analysis showed p38 phosphorylation
occurred in VPCs after treatment with SMC conditioned
medium for 20 minutes (Fig. 4E). p38 phosphorylation was
upregulated in response to mouse recombinant CCL2 and
CXCL1 treatment (Fig. 4F), and suppressed in response to con-
ditioned medium derived from CCL2 siRNA or CXCL1 siRNA
depleted SMCs (Fig. 4G). p38 phosphorylation was also sup-
pressed in VPCs where CCR2 or CXCR2 had been knocked
down using the corresponding shRNA (Fig. 4H). Pretreatment
of VPCs with CCR2 or CXCR2 antagonists consistently reduced
the p38 phosphorylation (Supporting Information Fig. 6C, 6D).
Importantly, p38 phosphorylation was signiﬁcantly reduced in
VPCs pretreated with NSC23766 but not ML141 (Fig. 4I, 4J).
Finally, migration of VPCs was reduced in the presence of
SB203580 (an inhibitor of the p38-MAPK signaling pathway)
(Fig. 4K). These indicate Rac1 regulates CCL2 and CXCL1
induced VPC migration via the p38 signaling pathway. RhoA,
as another important small GTPase has also been reported to
regulate the cell migration process [21], however, pretreat-
ment of VPCs with C3 transferase (an inhibitor of RhoA), did
not alter VPC migration or p38 phosphorylation (Supporting
Information Fig. 7). We, therefore, conclude that CCL2 and
CXCL1 induce VPC migration by activating GTPase Rac1 and
p38 signaling pathways.
Lack of CCL2 Inhibits Sca-11 Cell Migration and
Neointima Formation
SMCs can be described as activated and switched into the
synthetic phenotype when they are cultured in vitro [24] and
under these conditions they constitutively release CCL2 and
CXCL1. To study chemokine release in in vivo conditions, a
mouse femoral artery wire injury model was used to assess
whether native SMCs only produce chemokines which attract
VPC migration after cell injury. Coimmunoﬂuorescence stain-
ing of a-SMA and CCL2 or CXCL1 showed that in intact ves-
sels, SMCs are quiescent and do not produce CCL2 or CXCL1.
However, once SMCs are injured they release increasing levels
of CCL2 and CXCL1 (both at a short time point (6 hours) and
a long time point (2 weeks) (Supporting Information Fig. 8).
These chemokines could be potent and persistent attractants
for VPC migration. To verify this, GFP-Sca-11-VPCs, addition-
ally labeled using a Qtracker 655 Cell Labeling Kit, were
seeded on the adventitia of vessels which were injured. En
face confocal microscopy revealed that 72 hours after injury
the number of migrated cells found on the intimal side of the
vessel wall was signiﬁcantly lower in CCL22/2 mice when
compared to WT mice (Fig. 5A, Supporting Information Fig.
10A). CCL22/2 mice were identiﬁed by genotyping mice and
measuring CCL2 levels in peripheral blood (Supporting Infor-
mation Fig. 9A, 9B). Quantiﬁcation based on either GFP-Sca-
11-VPCs or Qtracker showed similar results (Fig. 5B, Support-
ing Information Fig. 10B). Sca-1 immunoﬂuorescence staining
in sections of injured arteries 2 weeks postinjury, showed that
GFP-Sca-11-VPCs remained Sca-1 positive after 2 weeks in
vivo but that fewer migrated into the intimal side to contrib-
ute to neointima formation in CCL22/2 mice compared to the
WT mice (Fig. 5C–5E). These results suggest a role for CCL2 in
VPC migration from the adventitia to the intima where they
may contribute to neointima formation.
To further investigate the role of CCL2 in VPC neointima
formation, wire-injured femoral arteries were seeded with
VPCs or PBS in the adventitia. HE stained sections showed
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neointima formation in the vessel at 1 or 2 weeks after wire
injury (Fig. 6A, 6B). Quantiﬁcation of the data indicated that
neointimal lesions were signiﬁcantly increased in vessels
seeded with VPCs. In the 2 week postinjury group, the differ-
ence in ratio of neointima to media with VPCs or PBS was
higher than that in the 1 week group. However, neointimal
lesions in CCL22/2 mice were decreased in vessels with either
VPCs seeded in the adventitia or PBS. There is a signiﬁcant
reduction in neointimal lesions area of vessels with VPC seed-
ing in CCL22/2 mice when compared to the WT mice at 2
weeks.
To characterize cells contributing to neointima formation,
immunoﬂuorescence staining of a-SMA and Sca-1 was used,
which showed that the cells in the neointima of PBS treated
vessels were approximately 70% a-SMA1 and 10% Sca-11 2
weeks after injury (Supporting Information Fig. 11). Staining
of a-SMA and CCR2 in Figure 6 revealed that cell numbers in
neointima of VPC seeded vessels were increased, although
Figure 3. SMC conditioned medium induced VPC migration by up-regulating expression of CCR2 and CXCR2. (A): Cluster grams show
the expression of 84 chemokine receptors, chemokine and other chemotactic cytokines on the untreated smooth muscle cells, clones
and Sca-11 VPCs individually. A row in the cluster represents a cell line, and relative level of expression for a gene is arranged in col-
umn. The magnitude of gene expression increases from green to red. The dendrogram of the different cell lines clustering is displayed
aside and describes the degree of relatedness among different cell lines. Quantiﬁcation was performed with three different batches of
each cell line. The vascular progenitor cells were treated with or without SMC conditioned medium for 18 hours, untreated cells served
as controls. n5 3. The mRNA (B, D) and cell-surface protein (C, E) expression of CCR2 or CXCR2 was conﬁrmed using real-time quantita-
tive PCR and ﬂow cytometry. n5 3. (F): Vascular progenitor cells were infected with lentiviral short hairpin RNA (shRNA) (noncoding
shRNA, CCR2 shRNA or CXCR2 shRNA) for ablation of CCR2 or CXCR2 before migration toward SMC conditioned medium. The noncoding
shRNA served as the control. n5 3. Scale bars, 100 mm. All graphs are shown as mean6 SEM. *p< .05, **p< .01, ***p< .001. Abbrevi-
ations: CM, SMC conditioned medium; ctrl, control, serum free medium; NCsh, noncoding shRNA; shCCR2, CCR2 shRNA; shCXCR2,
CXCR2 shRNA; SMC, smooth muscle cell; VPCs, vascular progenitor cells.
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Figure 4. Smooth muscle cell (SMC) induces vascular progenitor cells (VPCs) migration via activated GTPase Cdc42 and Rac1 and p38 sig-
naling pathway. (A, B): Pull down assays were performed on VPCs treated with either CCL2 or CXCL1 for 5 minutes. The transwell assay
was performed on VPCs that were pretreated with either vehicle, DMSO or ML141 (20 mM) (C), NSC23766 (50 mM) (D), SB203580 (10mM)
(K) for 1 hour before migration toward either SMC conditioned medium or recombinant CCL2, CXCL1. Scale bars, 100mm. The quantiﬁcation
of transwell assay shows as the fold of changes compared with cell migrated toward each treatment pre-treated with vehicle or DMSO.
Western blotting was performed on SMC conditioned medium (E), CCL2 or CXCL1 (F), SMCs (transfected with CCL2 siRNA or CXCL1 siRNA)
conditioned medium (G)-treated VPCs for the detection of p-p38 and t-p38. (H): Cell lysates from CCR2 shRNA or CXCR2 shRNA transfected
VPCs cultured in the SMC conditioned medium were harvested for the detection of the p-p38 and t-p38. Untreated cells served as the
controls. (I, J): After pre-treated with ML141, NSC23766 for 1 hour, VPC were stimulated by SMC conditioned medium or CCL2, CXCL1
before cell lysates were harvested for detection of the p-p38 and t-p38. All the blots shown are representative of three separate experi-
ments. All graphs are shown as mean6 SEM. n 5 3. *p< .05, **p< .01, ***p< .001. Abbreviations: CM, SMC conditioned medium; ctrl,
control, serum free medium; DMSO, dimethyl sulfoxide; NCsh, noncoding shRNA; NCsi, noncoding siRNA; p-p38, phosphorylated p38;
shCCR2, CCR2 shRNA; shCXCR2, CXCR2 shRNA; siCCL2, CCL2 siRNA; siCXCL1, CXCL1 siRNA; t-p38, total p38; vehicle, sterile distilled water.
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fewer were a-SMA1. These results indicate that in the PBS
treated vessels, most cells contributing to neointima forma-
tion are a-SMA1. These cells are either from media SMC
migration and proliferation or from progenitor cell differentia-
tion. When Sca-11 VPC were seeded in the adventitia, the
ratio of a-SMA1 cells was signiﬁcantly decreased which
implies that VPCs possess high potential to migrate and prolif-
erate. Over a short time most cells maintained their progeni-
tor cell characteristics, although several had differentiated
into SMCs (Fig. 6C, 6E). CCR2 was more highly expressed on
the cells in the neointima of VPC-seeded vessels (Fig. 6D, 6F).
These data suggest that VPCs applied to the adventitia
Figure 5. Lack of CCL2 inhibits Sca-11 cell migration in vivo. (A): Using a mouse femoral artery wire injury model, GFP-Sca-11-VPC (1 x
106) were seeded in the adventitia of each injured vessel. En face staining shows the cells were migrated to the intima side of the ves-
sels 72hrs post injury of WT and CCL22/2 mice. Scale bars, 25 mm. (B): The percentage of GFP-Sca-11-VPC within respective DAPI1 pop-
ulations in each view was quantiﬁed. (C): The femoral arteries sections from WT and CCL22/2 mice 2 weeks post injury were prepared
for immunoﬂuorescent Sca-1 staining. Scale bars, 50mm. (D, E): The graphs show the percentage of GFP-Sca-11-VPC or Sca-11 cells
within the DAPI1 cells in the neointima (white dotted line indicates internal elastin, the neointima area was surrounded by the line).
Representative images and graphs shown as mean6 SEM of n 5 8 mice/group. **p< .01, ***p< .001. Abbreviations: GFP-Sca-11-VPC,
GFP-Sca-11 vascular progenitor cells; Sca-11, stem cell antigen-1; WT, wild type.
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Figure 6. Lack of CCL2 reduces neointima formation and inhibits stem cell antigen-1 cells migration and differentiation into smooth
muscle cell (SMCs). (A): Animals were euthanized at indicated time points after injury, and the femoral arteries were ﬁxed in 4%
phosphate-buffered (pH5 7.2) formaldehyde, embedded in parafﬁn, sectioned in 5 mm, and stained with hematoxylin–eosin. Scale bars,
50 mm. (B): The ratio of neointima (the area between arrows) to media was quantiﬁed as shown in the graph. (C, D): Vessel sections
were also prepared for immunoﬂuorescent a-SMA and CCR2 staining 2 weeks postwire injury (white dotted line indicates internal elas-
tin, and the above is neointima area). Scale bars, 50 mm. (E, F): Quantiﬁcation of the percentage of positively stained cells within the
neointima was shown in graphs as mean6 SEM of n5 8 mice/group. **p< .01, ***p< .001. Abbreviations: PBS, phosphate buffered
saline; VPC, vascular progenitor cell; WT, wild type.
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signiﬁcantly increase neointima formation after vessel injury,
largely through their migration although with a lesser effect due
to their differentiation into SMCs. Furthermore, lack of CCL2
markedly inhibits the effect of VPCs on neointima formation.
Role of CCL2 Released from Nonbone Marrow Tissue
CCL2 is not only released from bone marrow cells but also
from SMCs, endothelial cells, and other tissues [9, 25]. To
investigate which source of CCL2 plays the most important
role in neointima formation due to VPC migration chimeric
mouse models were created. Wild-type bone marrow was
transplanted into an irradiated CCL22/2 mouse to form a
CCL2 chimera. Conversely, a wild-type chimeric mouse model
was prepared by transplanting CCL22/2 mouse bone marrow
cells into an irradiated wild-type mouse. The levels of CCL2 in
serum of peripheral blood were measured using a murine
CCL2 ELISA kit. In the wild-type chimeric mouse model, the
level of CCL2 in peripheral blood was increased despite trans-
plantation with CCL22/2 bone marrow when compared to a
nontransplanted wild-type mouse control, indicating that CCL2
is mostly released from nonbone marrow tissue. In contrast,
the level of CCL2 was increased in CCL22/2 mice with trans-
planted wild-type bone marrow cells, but to a much lesser
extent, indicating that only a small proportion of CCL2 is
released from bone marrow derived cells (Fig. 7A). Data from
HE stained sections showed that neointima lesion area corre-
lated with the CCL2 level in blood (Fig. 7B, 7C). These results
support the observations that CCL2 induced VPC migration
contributes to neointima formation.
CXCL1 Plays a Role in Sca-1 Positive Cell
Migration In Vivo
Previous studies have demonstrated that CXCL1 can induce
endothelial cell migration and tube formation in vitro [26]
and also acts as an angiogenic factor to promote tumor
growth [27]. To further investigate the role of CXCL1 in induc-
tion of VPC migration in vivo, VPCs were mixed with matrigel
containing either PBS or mouse recombinant CXCL1 and
injected subcutaneously. After 2 weeks, the number of cells
that migrated into the matrigel was signiﬁcantly increased in
the CXCL1 group when compared to PBS controls (Supporting
Information Fig. 12A). Immunoﬂuorescence staining of Sca-1,
CD31 and a-SMA showed that most of the migrated cells in
the matrigel plug were Sca-1 positive, whilst some were CD31
positive, and only very few were a-SMA positive (Supporting
Information Fig. 12B). In addition, CXCL1 or control siRNA
within the pluronic gel was delivered to the adventitial side
of wire injured vessels to assess the effect of local CXCL1
knockdown on Sca-11 VPC migration in vivo. Successful in
vivo knockdown of CXCL1 mRNA level in injured femoral
arteries was conﬁrmed after 6 days using real time quantita-
tive PCR (Supporting Information Fig. 13A). Furthermore, En
face confocal microscopy revealed that 72 hours after seeding
GFP-Sca-11 VPC in the adventitia, the number of migrated
cells found on the intimal side of the vessel wall was lower in
CXCL1 siRNA treated vessels compared to the control siRNA
(Supporting Information Fig. 13B). These results indicate the
important role of CXCL1 in Sca-11 cells migration in vivo.
DISCUSSION
Restenosis is still the main complication that exacerbates the
outcome of coronary artery disease after percutaneous coro-
nary intervention [28–30]. SMC proliferation and migration
are suggested to be important factors in development of neo-
intimal hyperplasia and restenosis [31]. In the present study,
we identify a new mechanism of smooth muscle accumulation
in neointimal lesions after vascular injury, in which vascular
Figure 7. CCL2 released from peripheral tissue plays an important
role in contribution of the neointima formation. (A) Using chimeric
mice model, the CCL2 in peripheral blood of indicated mice was
subjected to a CCL2 Quantikine ELISA kit. The vessels sections of
indicated mice at various time points were stained with hematoxy-
lin–eosin, and the neointima area (the area between arrows) was
shown in the represented images (B) scale bars, 50mm., and quanti-
ﬁed in the graphs (C) shown as mean6 SEM of n5 5 mice/group.
*p< .05, **p< .01, ***p< .001. Abbreviations: WT1 CCL22/2
BMT, wild type mice of which bone marrow was transplanted from
CCL22/2mice; CCL22/21WT BMT, CCL22/2 mice of which bone
marrow was transplanted from wild type mice.
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stem/progenitor cells migrate from the adventitia to the
intima. We demonstrate that proliferating SMCs can release
several chemokines, including CXCL1 and CCL2, which have a
role in attracting these vascular progenitors. Single cell tracking
experiments indicate that cells are migrate directionally and
efﬁciently but not randomly. Importantly, perivascular applica-
tion of GFP-Sca-11-VPC to injured arteries signiﬁcantly
enhanced neointimal lesion formation via progenitor migration.
This effect is diminished by CCL2 knockout. We provide the ﬁrst
evidence that the SMC-produced chemokine CCL2 is crucial for
vascular progenitor migration from the adventitia to the intima
where these cells contribute to lesion formation.
After endothelial injury, an inﬂammatory response occurs in
the vessel wall, and chemokines are released by both mononu-
clear cells and SMCs [32, 33]. Using multiple chemokine ELISA
we demonstrated that several chemokines were upregulated in
cultured SMCs and amongst them, CXCL1, CCL2 and CCL5 were
secreted at the highest levels. To further conﬁrm the effects of
these chemokines, we stimulated stem cells with exogenous
mouse recombinant proteins and found that CCL2 and CXCL1
signiﬁcantly induced vascular progenitor migration. Previous
studies have reported that CCL5 mediates trafﬁcking and hom-
ing of T cells, monocytes, basophils and eosinophils [34–37].
However, it does not appear to play such a role in induction of
progenitor migration, indicating that vascular stem cells may
selectively or speciﬁcally respond to certain chemokines.
Chemokine receptors are expressed on many different cell
types, such as granulocytes, monocytes, mast cells, T cells, and
endothelial cells [38, 39], but no prior study has shown the
presence or absence of chemokine receptors on vascular pro-
genitors. We used a qPCR array to proﬁle the expression of
chemokines, cytokines, and their receptors in different vessel
wall cell lines. The results showed the presence of most cyto-
kines and chemokine receptors in a mixed population of Sca-
11 progenitor cells derived by magnetic sorting and one clone
of Sca-11 progenitor cells and although SMCs display a higher
expression level of different chemokine receptors. This distinct
chemokine receptor proﬁle marks a distinction between mature
SMCs and progenitors. Expression of CCL2 and CXCL1 was
much higher on SMCs compared to other cells, which was simi-
lar to our ﬁnding at the protein level of CCL2 and CXCL1 in
SMCs as measured in the ELISA array. As many reports have
demonstrated, CCL2/CCR2 and CXCL1/CXCR2 signal transduction
mediates recruitment of neutrophils, monocytes or macro-
phages into inﬂammatory sites during progression of different
kinds of disease [12, 40–43]. In our study, we found that both
CCR2 and CXCR2 were upregulated on VPCs after treatment
with SMC-derived chemokines. The ability of VPCs to migrate
after CCR2 and CXCR2 genes were permanently silenced by
shRNA was signiﬁcantly reduced. This indicates that SMC-
released CCL2 and CXCL1 activate their corresponding receptors
on vascular stem/progenitor cells.
In order to elucidate the mechanism of cell migration, we
studied the role of the Rho GTPase family. Rac1, Cdc42 and
RhoA, as the main Rho GTPase family members, regulate the
formation of lamellipodia, ﬁlipodia and focal adhesions, respec-
tively [44]. In the present study, we found both Cdc42 and
Rac1 in VPCs were activated by CCL2 and CXCL1 and inhibition
of either Cdc42 or Rac1 impaired VPC migration in response to
CCL2 or CXCL1. Cytokines such as IL-4 and TNF-a can activate
stress-activated pathways leading to phosphorylation of p38
MAPK which is dependent on Rac1 and Cdc42 [45, 46]. In our
study, p38 phosphorylation was upregulated in response to
mouse recombinant CCL2/CXCL1, and p38 phosphorylation was
suppressed by CCL2/CXCL1 knockdown or CCR2/CXCR2 inhibi-
tion. These results suggest that progenitor migration is induced
through a p38 MAPK signaling pathway. Importantly, we also
found that p38 phosphorylation was markedly downregulated
by Rac1 inhibition but not inhibition of Cdc42 or RhoA, sug-
gesting that progenitor migration is induced via a Rac1/p38 sig-
naling pathway. Although the migration assay showed the
participation of Cdc42 in SMC induced progenitor migration, it
may through an as yet unidentiﬁed signaling pathway.
As the above results show that CCL2 and CXCL1 contribute
to VPC migration equally, we wanted to further investigate pos-
sible interactions between the two chemokines. Depletion of
each chemokine was found to partially inhibit VPCs migration,
but treatment with each chemokine individually failed to stimu-
late VPCs to release the other. After loss of one chemokine,
the induction of VPCs migration is not compensated by the
other chemokine. Simultaneous depletion of both chemokines
did not further inhibit VPC migration when compared to inhibi-
tion of a single chemokine. The effects of CCL2 and CXCL1 in
the mediation of VPCs migration were found to be neither
cumulative nor redundant. However, there may also be addi-
tional factors in SMC conditioned medium which play a role in
inducing VPC migration, as migration was not completely abol-
ished on depletion of both chemokines. We have shown that
both chemokines induce VPC migration through the Rac1/p38
signaling pathway but act through their own receptors. Previ-
ous studies [47, 48] have shown that chemokine receptors can
form coreceptors to mediate their effects, thus further studies
need to be performed to determine whether CCR2 and CXCR2
form a coreceptor to induce VPC migration.
Reports using different animal models have shown that
CCL2 plays an important role in neointimal hyperplasia [49–51],
for example CCL2 enhances SMC migration, proliferation and
invasion to remodel vessels [52, 53]. VPCs have also previously
been identiﬁed as playing a role in neointima formation [17,
19]. In the present study, we demonstrated that migrating pro-
genitors are an important cellular component of CCL2 mediated
neointima formation. We found CCL2 not only enhanced VPC
migration from the adventitia to the intima in a short time
period but also accelerated neointima formation by inducing
VPC migration. We also identiﬁed that the majority of cells con-
tributing to neointima formation are not SMC marker positive
but express a stem cell marker (Sca-1), which indicates that
although some VPCs participate in neointima formation and dif-
ferentitate into SMCs, most of them retain progenitor cell char-
acteristics as they migrate into the neointima.
The expression of CCR2 in neointimal cells suggests that the
participtation of VPCs in neointima formation may be dependent
on CCL2-driven recruitment. Vande et al demonstrated the main
source of CCL2 is bone marrow-derived monocytes [54]. In our
study, through use of chimeric mouse models, we found that after
bone marrow transplant, CCL2 can be detected in the peripheral
blood of a CCL22/2 chimeric mouse (bone marrow was from WT
mouse), where it was originially undetectable. This conﬁrms the
ﬁndings of previous studies [54]. However, in a WTchimeric mouse
(bone marrow was from CCL22/2 mouse), the levels of CCL2 were
markedly upregulated and showed an even higher increase com-
pared to the CCL22/2 chimeric mouse. This indicates that CCL2
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from nonbone marrow tissues (e.g., SMC) contributes more to the
global CCL2 levels in the peripheral blood than bone marrow.
Quantitative data from neointimal lesions further conﬁrms that
CCL2 from nonbone marrow tissues-induces progenitor migration
which contributes to neointima formation. Taken together, CCL2
released from nonbone marrow tissues (e.g., SMC) accelerates
neointima formation through induction of progenitor migration
from adventitia to neointima.
It was believed that neointimal formation in response to
endothelial injury was mainly due to cell accumulation via
recruiting inﬂammatory cells [55, 56] and SMCs [57, 58] from
the media. In this study, we utilized an accelerated model of
in vivo neointima formation by inducing endothelial injury.
From the data generated in non-VPC seeded groups, we
found that during the short time period of 1-2 weeks very
few cells contributed to the spontaneous development of
neointimal lesions. In contrast, an obvious neointima was
found in VPC seeded groups, which suggested that the neoin-
tima formation is largely generated by VPCs migration in the
early stage of the model. These ﬁndings have two implica-
tions. First, the cells accumulating in neointimal lesions may
be derived from migration/proliferation of vascular stem cells,
which can differentiate into SMC-like cells, although mononu-
clear cells and medial SMCs contribute to the process. To
obtain quantative data on how many cells in neointimal
lesions are derived from progenitor cells, lineage tracing for
progenitor cells in animal models would be essential. Sec-
ondly, a new treatment strategy for restenosis could be con-
sidered. Current treatments used in clinical are based on
inhibition of cell proliferation [59, 60], for example, sirolimus.
A recent report from our group suggests that sirolimus can
enhance vascular stem/progenitor cell differentiation into
SMCs, but inhibits endothelial differentiation [18]. Our current
ﬁndings that large numbers of stem/progenitor cells are
recruited to the intima in response to CCL2 and CXCL1 pro-
vide a potential to direct cell differentiation into the endothe-
lial lineage. In other words, a high number of stem cells exist
during neointima formation, which could differentiate into
endothelial cells if a new drug coated stent could harness
their potential and directed them speciﬁcally.
SUMMARY
Taken together, these results may provide crucial answers as to
why restenosis and delayed re-endothelialization persist after
angioplasty and stenting, which may be fundamental for develop-
ing new drugs that can improve the long-term outcome of
patients.
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